The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison between nivolumab plus ipilimumab, FOLFOX and nivolumab plus FOLFOX therapy as first-line treatment for cisplatin-unfit advanced esophageal squamous cell carcinoma.
 
Nozomu Ogura
No Relationships to Disclose
 
Shun Yamamoto
Honoraria - Bristol-Myers Squibb Japan; Merck Sharp and Dohme; Ono Pharmaceutical; Taiho Pharmaceutical
 
Ryuichi Morita
No Relationships to Disclose
 
Hiroshi Imazeki
No Relationships to Disclose
 
Hideaki Takahashi
No Relationships to Disclose
 
Yoshitaka Honma
Honoraria - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly; Merck Serono; MSD; Novartis; Nutrisystem; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Consulting or Advisory Role - Janssen; Rakuten Medical Japan
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly; Merck Serono; MSD; Novartis; Nutrisystem; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Adlai Nortye (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Maruho (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical Japan (Inst); Taiho Pharmaceutical (Inst)
 
Daisuke Kurita
No Relationships to Disclose
 
Koshiro Ishiyama
No Relationships to Disclose
 
Hiroyuki Daiko
No Relationships to Disclose
 
Yasuyuki Seto
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Beigene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)